Applications of 1-Cyclohexyl-3-(2-Morpholinoethyl)Carbodiimide Metho-P-Toluenesulfonate in Industrial Manufacturing

As the direct manufacturer of 1-Cyclohexyl-3-(2-Morpholinoethyl)Carbodiimide Metho-P-Toluenesulfonate, we support advanced applications across peptide synthesis, pharmaceutical manufacturing, biopolymer modification, oligonucleotide assembly, specialty resin modification, diagnostic reagent production, and advanced material science. Each sector applies this reagent with distinct formulation requirements, processing steps, and final product specifications established by industry standards and regulatory guidance.

1. Peptide Synthesis—Condensation Reagent in Pharmaceutical APIs

Pharmaceutical companies leverage this carbodiimide-based reagent for solution-phase and solid-phase peptide synthesis processes, specifically for facilitating amide bond formation between protected amino acids. The material’s efficiency at activating carboxyl groups while minimizing racemization enables high yield synthesis of both simple dipeptides and complex active pharmaceutical ingredients (APIs). Strict adherence to cGMP conditions remains vital. In downstream processes, the reagent integrates post-deprotection during elongation cycles, followed by precise work-up and purification. Typical end products include generic peptide therapeutics, custom research peptides, and bioactive peptide components in finished drug formulations.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 210/211
• EU EudraLex Volume 4 GMP for APIs
• USP General Chapter <1047> Peptide APIs

Typical usage ratio

• 0.95 – 1.2 molar equivalents to carboxyl component, typically adjusted by scale and side-chain protection requirements

Downstream process integration

• Added during peptide coupling sequences after removal of temporary protecting groups; typically dissolved in DMF or NMP solvent systems; followed by removal through aqueous washes and HPLC purification

Final product types

• Therapeutic peptides (API grade)
• Research-use-only peptide products
• Diagnostic peptide conjugates
• Cosmeceutical oligopeptides

2. Oligonucleotide Synthesis—Activation Agent for Nucleic Acid Coupling

Nucleotide manufacturers employ this carbodiimide to activate terminal phosphate groups, promoting efficient internucleotide phosphoramidate or ester bond formation during solid-phase oligonucleotide assembly. Reactive intermediates formed enable higher coupling yields for long DNA or RNA sequences. Dosing precision depends on oligonucleotide length and resin loading. Process integration occurs after detritylation and activation of the 5’ or 3’ site. The material’s use requires traceability and thorough post-coupling cleavage from scaffolds to achieve nucleic acid APIs that meet purity and residual trace contaminant guidelines.

Industry compliance standards

• USP <1207> Nucleic Acid-Based Drug Substances
• Ph. Eur. 5.14 Oligonucleotide APIs
• ISO 13485 for Diagnostic DNA/RNA Manufacturing
• OECD Principles of Good Laboratory Practice

Typical usage ratio

• 0.9 – 1.1 molar equivalents to terminal phosphate group; fine-tuned by oligonucleotide length and solid-phase resin capacity

Downstream process integration

• Fed during the coupling stage in phosphoramidite DNA/RNA synthesis cycles on automated synthesizers; followed by cleavage and extensive desalting by reverse-phase or ion-exchange chromatography

Final product types

• Antisense oligonucleotide APIs
• siRNA and miRNA clinical candidates
• Custom research oligonucleotide probes
• qPCR and clinical diagnostic primers

3. Biopolymer Functionalization—Crosslinking in Medical Hydrogels

Medical device and biomaterial producers rely on this reagent to mediate carbodiimide crosslinking between carboxyl and amine groups on biopolymer chains such as gelatin, hyaluronan, or collagen. The resulting amide bonds produce stable, biocompatible hydrogel networks used in drug delivery matrices and wound care. Process parameters demand precise control to ensure residual levels comply with medical implant standards. Engineers introduce the raw material during slurry mixing or in-situ crosslinking baths, balancing reaction time to control swelling and mechanical properties of the finished hydrogel.

Industry compliance standards

• ISO 10993 Biocompatibility Evaluation
• 21 CFR 820 Quality System Regulation
• USP Class VI Biological Reactivity
• ISO 13485 Medical Device QMS

Typical usage ratio

• 1.0 – 2.0 molar equivalents to free carboxyl groups on polymer backbone, adjusted to balance crosslinking density with desired elasticity and swelling ratio

Downstream process integration

• Dispersed during initial polymer solution preparation; reaction carried out under neutral to slightly acidic pH; hydrogel shaped and washed to remove unreacted components before sterilization

Final product types

• Injectable hydrogels for minimally invasive therapy
• Bioactive wound dressings
• Drug-eluting hydrogel implants
• Ophthalmic gel carriers

4. Specialty Resin Modification—Custom Crosslinker in Epoxy and Acrylic Systems

Resin formulators integrate this compound as a carbodiimide-based crosslinking additive to enhance mechanical strength, chemical resistance, and adhesion properties in high-performance epoxy and acrylic resin systems. Its morpholine and cyclohexyl substituents impart controllable reactivity for applications demanding durable, heat- and solvent-resistant surfaces. Typical process use involves introduction during batch blending prior to curing stage. Manufacturers must verify compatibility with pigments and other modifiers to avoid phase separation or gelation. Finished resins serve demanding industrial coating and electronics adhesive markets.

Industry compliance standards

• ISO 9001:2015 Quality Management
• REACH Registration and SDS
• IEC 61249-2-21 Halogen-Free Requirement (electronics encapsulation)
• ASTM D1652 for Epoxy Resins

Typical usage ratio

• 0.2 – 1.2 weight percent relative to total resin, optimized through iterative testing based on desired tensile, shear strength, and heat distortion temperature

Downstream process integration

• Added during resin prepolymer mixing phase; thoroughly dispersed prior to hardener or catalyst addition; compound becomes covalently bonded in crosslinked matrix upon final cure

Final product types

• High-build industrial coatings
• Semiconductor encapsulation compounds
• UV-cure acrylic adhesives
• Fiber-reinforced composite prepregs

5. Diagnostic Reagent Production—Stabilization Reagent for Protein Conjugates

Diagnostic kit manufacturers value this innovation as a coupling reagent for preparing stable protein conjugates required for immunoassay reagent formulations. Controlled activation enables covalent bonding between antibodies and reporter enzymes or other detection molecules. Precise dosing ensures minimum conjugate alteration, preserving antigen recognition. The reagent enters the production flow after protein purification and buffer adjustment. Final wash steps must reduce residual levels to meet analytical-grade purity. End-use marker conjugates, calibration reagents, and standard assay kits reflect customer-specific sensitivity and reproducibility needs.

Industry compliance standards

• ISO 13485:2016 for In Vitro Diagnostics (IVD)
• CLSI EP05-A3 Precision Requirements for Immunoassays
• US FDA 21 CFR Part 820 (IVD QSR)
• ISO 23640 In Vitro Diagnostic Stability Testing

Typical usage ratio

• 1.0 – 1.5 molar equivalents to target protein functional groups, titrated based on protein size and preservative content in buffer

Downstream process integration

• Coupling step performed post-buffer exchange; reaction proceeds at controlled pH and temperature; followed by size-exclusion or affinity chromatography to separate conjugated products from unreacted components

Final product types

• Conjugated antibodies for ELISA and lateral flow tests
• Enzyme-labeled reagents for chemiluminescence assays
• Diagnostic standard calibration solutions
• Clinical control materials